{
    "id": "99ab6459-db02-4abd-9689-6c4c43021119",
    "indications": {
        "text": "abiraterone acetate tablets indicated combination prednisone treatment patients \u2022metastatic castration-resistant prostate cancer ( crpc ) \u2022metastatic high-risk castration-sensitive prostate cancer ( cspc )",
        "doid_entities": [
            {
                "text": "prostate cancer (DOID:10283)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10283"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "metastatic castration-resistant prostate cancer : \u2022 abiraterone acetate tablets 1,000 mg orally daily prednisone 5 mg orally twice daily . ( 2.1 ) metastatic castration-sensitive prostate cancer : \u2022 abiraterone acetate tablets 1,000 mg orally daily prednisone 5 mg orally daily . ( 2.2 ) patients receiving abiraterone acetate tablets also receive gonadotropin-releasing hormone ( gnrh ) analog concurrently bilateral orchiectomy . abiraterone acetate tablets must taken single dose daily empty stomach . eat food 2 hours 1 hour taking abiraterone acetate tablets . tablets must swallowed whole water . crush chew tablets . ( 2.3 ) dose modification : \u2022 patients baseline moderate hepatic impairment ( child-pugh class b ) , reduce abiraterone acetate tablets starting dose 250 mg daily . ( 2.4 ) \u2022 patients develop hepatotoxicity treatment , hold abiraterone acetate tablets recovery . retreatment may initiated reduced dose . abiraterone acetate tablets discontinued patients develop severe hepatotoxicity . ( 2.4 )",
        "doid_entities": [
            {
                "text": "prostate cancer (DOID:10283)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10283"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "abiraterone acetate tablets , usp available containing 250 mg 500 mg abiraterone acetate , usp . 500 mg film-coated tablets : 500 mg tablets white , film-coated , oval , unscored tablets debossed one side tablet ab500 side . available follows : ndc 0378-6921-91bottles 60 tablets 250 mg uncoated tablets : 250 mg tablets white off-white , oval , unscored tablets debossed one side tablet ab250 side . available follows : ndc 0378-6920-78bottles 120 tablets storage handling : store 20\u00ba 25\u00bac ( 68\u00ba 77\u00baf ) ; excursions permitted range 15\u00ba 30\u00bac ( 59\u00ba 86\u00baf ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp using child-resistant closure . keep reach children . based mechanism action , abiraterone acetate tablets may harm developing fetus . women pregnant women may pregnant handle abiraterone acetate 250 mg uncoated tablets abiraterone acetate tablets broken , crushed , damaged without protection , e.g . , gloves [ ( 8.1 ) ] .",
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "ABIRATERONE ACETATE",
            "code": "EM5OCB9YJ6",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68639"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2910 (50 MPA.S)",
            "code": "1IVH67816N",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_181906"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        }
    ],
    "organization": "Mylan Pharmaceuticals Inc.",
    "name": "Abiraterone Acetate",
    "effectiveTime": "20250315",
    "indications_original": "Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with \n                  \n                     \n                        \u2022Metastatic castration-resistant prostate cancer (CRPC)\n                     \n                        \u2022Metastatic high-risk castration-sensitive prostate cancer (CSPC)",
    "contraindications_original": "Metastatic castration-resistant prostate cancer: \u2022 Abiraterone acetate tablets 1,000 mg orally once daily with prednisone 5 mg orally twice daily. ( 2.1 ) Metastatic castration-sensitive prostate cancer: \u2022 Abiraterone acetate tablets 1,000 mg orally once daily with prednisone 5 mg orally once daily. ( 2.2 ) Patients receiving abiraterone acetate tablets should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. Abiraterone acetate tablets must be taken as a single dose once daily on an empty stomach. Do not eat food 2 hours before and 1 hour after taking abiraterone acetate tablets. The tablets must be swallowed whole with water. Do not crush or chew tablets. ( 2.3 ) Dose Modification: \u2022 For patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the abiraterone acetate tablets starting dose to 250 mg once daily. ( 2.4 ) \u2022 For patients who develop hepatotoxicity during treatment, hold abiraterone acetate tablets until recovery. Retreatment may be initiated at a reduced dose. Abiraterone acetate tablets should be discontinued if patients develop severe hepatotoxicity. ( 2.4 )",
    "warningsAndPrecautions_original": "Abiraterone Acetate Tablets, USP are available containing 250 mg or 500 mg of abiraterone acetate, USP.\n                  \n                     500 mg film-coated tablets: The 500 mg tablets are white, film-coated, oval, unscored tablets debossed with M on one side of the tablet and AB500 on the other side. They are available as follows:\n                  NDC 0378-6921-91bottles of 60 tablets\n                  \n                     250 mg uncoated tablets: The 250 mg tablets are white to off-white, oval, unscored tablets debossed with M on one side of the tablet and AB250 on the other side. They are available as follows:\n                  NDC 0378-6920-78bottles of 120 tablets\n                  \n                     \n                        Storage and Handling: Store at 20\u00ba to 25\u00baC (68\u00ba to 77\u00baF);\u00a0excursions permitted in the range from 15\u00ba to 30\u00baC (59\u00ba to 86\u00baF) [see USP Controlled Room Temperature].\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  Keep out of reach of children.\n                  Based on its mechanism of action, abiraterone acetate tablets may harm a developing fetus. Women who are pregnant or women who may be pregnant should not handle abiraterone acetate 250 mg uncoated tablets or other abiraterone acetate tablets if broken, crushed, or damaged without protection, e.g., gloves [see Use in Specific Populations (8.1)].",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Abiraterone Acetate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68639"
        }
    ]
}